Publications
2012
Nguyen-Hoai T; Baldenhofer G; Ahmed MS; Pham-Duc M; Gries M; Lipp M; Doerken B; Pezzutto A; Westermann J
CCL19 (ELC) improves TH1-polarized immune responses and protective immunity in a murine Her2/neu DNA vaccination model
Journal of Gene Medicine 14 (2): 128-137 (2012-02)
Nguyen-Hoai T; Baldenhofer G; Sayed Ahmed MS; Pham-Duc M; Vu MD; Lipp M; Doerken B; Pezzutto A; Westermann J
CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model
Cancer Gene Therapy 19 (1): 69-76 (2012)
2011
Waiczies H; Lepore S; Janitzek N; Hagen U; Seifert F; Ittermann B; Purfuerst B; Pezzutto A; Paul F; Niendorf T; Waiczies S
Perfluorocarbon particle size influences magnetic resonance signal and immunological properties of dendritic cells
PLoS ONE 6 (7): e21981 (2011-07-19)
Westermann J; Floercken A; Willimsky G; van Lessen A; Kopp J; Takvorian A; Joehrens K; Lukowsky A; Schoenemann C; Sawitzki B; Pohla H; Frank R; Doerken B; Schendel DJ; Blankenstein T; Pezzutto A
Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study
Gene Therapy 18 (4): 354-363 (2011-04)
2010
Buchner A; Pohla H; Willimsky G; Frankenberger B; Frank R; Baur-Melnyk A; Siebels M; Stief CG; Hofstetter A; Kopp J; Pezzutto A; Blankenstein T; Oberneder R; Schendel DJ
Phase I trial of an allogeneic gene-modified tumor cell vaccine (RCC-26/CD80/IL-2) in patients with metastatic renal cell carcinoma
Human Gene Therapy 21 (3): 285-297 (2010-03)
2009
Westermann J; Hecker AC; Floercken A; Doerken B; Pezzutto A
Granulocyte macrophage-colony stimulating factor plus interleukin-2 plus alpha-interferon plus 5-fluorouracil in the treatment of metastatic renal cell cancer: induction of CD80/86+ T cells indicates adverse outcome
Journal of Immunotherapy 32 (6): 667-675 (2009-07)
2008
Morschhauser F; Seymour JF; Kluin-Nelemans HC; Grigg A; Wolf M; Pfreundschuh M; Tilly H; Raemaekers J; van't Veer MB; Milpied N; Cartron G; Pezzutto A; Spencer A; Reyes F; Dreyling M
A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma
Annals of Oncology 195 (2): 247-253 (2008-02)
2007
Westermann J; Kopp J; van Lessen A; Hecker AC; Baskaynak G; le Coutre P; Doehner K; Doehner H; Doerken B; Pezzutto A
Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia
British Journal of Haematology 137 (4): 297-306 (2007-05)
Westermann J; Nguyen-Hoai T; Baldenhofer G; Hoepken UE; Lipp M; Doerken B; Pezzutto A
CCL19 (ELC) as an adjuvant for DNA vaccination: induction of a TH1-type T-cell response and enhancement of antitumor immunity
Cancer Gene Therapy 14 (6): 523-532 (2007-06)
2006
Sebelin K; Schulzki A; Kloetzel PM; Doerken B; Pezzutto A; Subklewe M
Impairment of circulating myeloid dendritic cells in immunosuppressed renal/pancreas transplant recipients
Transplantation 82: 779-787 (2006-09-27)
Salmon D; Aido-Machado R; Diehl A; Leidert M; Schmetzer O; de Lima AP; Scharfstein J; Oschkinat H; Pires JR
Solution structure and backbone dynamics of the Trypanosoma cruzi cysteine protease inhibitor chagasin
Journal of Molecular Biology 357: 1511-1521 (2006-04-14)
Westermann J; Lessen A; Schlimper C; Baskaynak G; Coutre P; Doerken B; Pezzutto A
Simultaneous cytokine analysis by cytometric bead array for the detection of leukaemia-reactive T cells in patients with chronic myeloid leukaemia
British Journal of Haematology 132: 32-35 (2006-01-01)
Subklewe M; Marquis R; Choquet S; Leblond V; Garnier JL; Hetzer R; Swinnen LJ; Oertel S; Papp-Vary M; Gonzalez-Barca E; Hepkema BG; Schoenemann C; May J; Pezzutto A; Riess H
Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantation
Transplantation 82: 1093-1100 (2006-10-27)
2005
Bienert M; Reisinger I; Srock S; Humplik BI; Reim C; Kroessin T; Avril N; Pezzutto A; Munz DL
Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: initial experience
European Journal of Nuclear Medicine and Molecular Imaging 32: 1225-1233 (2005-01-01)
Stuehmer T; Chatterjee M; Hildebrandt M; Herrmann P; Gollasch H; Gerecke C; Theurich S; Cigliano L; Manz RA; Daniel PT; Bommert K; Vassilev LT; Bargou RC
Non-genotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma
Blood 106: 3609-3617 (2005-08-04)
Frankenberger B; Pohla H; Noessner E; Willimsky G; Papier B; Pezzutto A; Kopp J; Oberneder R; Blankenstein T; Schendel DJ
Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs
Clinical Cancer Research 11: 1733-1742 (2005-01-01)
Schmetzer O; Moldenhauer G; Riesenberg R; Pires JR; Schlag PM; Pezzutto A
Quality of recombinant protein determines the amount of autoreactivity detected against the tumor-associated epithelial cell adhesion molecule antigen: low frequency of antibodies against the natural protein
Journal of Immunology 174: 942-952 (2005-01-01)
2004
Westermann J; Nguyen-Hoai T; Mollweide A; Richter G; Schmetzer O; Kim HJ; Blankenstein T; Doerken B; Pezzutto A
Flt-3 ligand as adjuvant for DNA vaccination augments immune responses but does not skew TH1/TH2 polarization
Gene Therapy 11: 1048-1056 (2004-01-01)
Westermann J; Schlimper C; Richter G; Mohm J; Doerken B; Pezzutto A
T cell recognition of bcr/abl in healthy donors and in patients with chronic myeloid leukaemia
British Journal of Haematology 125: 213-216 (2004-04-01)
Kim YM; Mapara MY; Down JD; Johnson KW; Boisgerault F; Akiyama Y; Benichou G; Pelot M; Zhao G; Sykes M
Graft-versus-host-reactive donor CD4 cells can induce T cell-mediated rejection of the donor marrow in mixed allogeneic chimeras prepared with nonmyeloablative conditioning
Blood 103: 732-739 (2004-01-15)
2003
Rubio MT; Kim YM; Sachs T; Mapara M; Zhao G; Sykes M
Antitumor effect of donor marrow graft rejection induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: critical role for recipient-derived IFN-gamma
Blood 102: 2300-2307 (2003-09-15)
Westermann J; Koerner IJ; Kopp J; Kurz S; Zenke M; Doerken B; Pezzutto A
Cryopreservation of mature monocyte-derived human dendritic cells for vaccination: influence on phenotype and functional properties
Cancer Immunology Immunotherapy 52 (3): 194-198 (2003-01-01)
Schlenk RF; Benner A; Hartmann F; del Valle F; Weber C; Pralle H; Fischer JT; Gunzer U; Pezzutto A; Weber W; Grimminger W; Preiss J; Hensel M; Froehling S; Doehner K; Haas R; Doehner H
Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial
Leukemia 17: 1521-1528 (2003-08-01)
2001
Richter G; Hayden-Ledbetter M; Irgang M; Ledbetter JA; Westermann J; Koerner I; Daemen K; Clark EA; Aicher A; Pezzutto A
Tumor necrosis factor-alpha regulates the expression of inducible costimulator receptor ligand on CD34+ progenitor cells during differentiation into antigen presenting cells
Journal of Biological Chemistry 276: 45686-45693 (2001-01-01)
2000
Panelli MC; Riker A; Kammula U; Wang E; Lee KH; Rosenberg SA; Marincola FM
Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases
Journal of Immunology 164: 495-504 (2000-01-01)
Aicher A; Hayden-Ledbetter M; Brady WA; Pezzutto A; Richter G; Magaletti D; Buckwalter S; Ledbetter JA; Clark EA
Characterization of human inducible costimulator ligand expression and function
Journal of Immunology 164: 4689-4696 (2000-05-01)
Nielsen MB; Monsurro V; Migueles SA; Wang E; Perez-Diez A; Lee KH; Kammula U; Rosenberg SA; Marincola FM
Status of activation of circulating vaccine-elicited CD8+ T cells
Journal of Immunology 165: 2287-2296 (2000-08-15)
1999
Aicher A; Shu GL; Magaletti D; Mulvania T; Pezzutto A; Craxton A; Clark EA
Differential role for p38 mitogen-activated protein kinase in regulating CD40-induced gene expression in dendritic cells and B cells
Journal of Immunology 163: 5786-5795 (1999-12-01)
Cayeux S; Richter G; Becker C; Pezzutto A; Doerken B; Blankenstein T
Direct and indirect T cell priming by dendritic cell vaccines
European Journal of Immunology 29: 225-234 (1999-01-01)
Daniel PT; Scholz C; Essmann F; Westermann J; Pezzutto A; Doerken B
CD95/Fas-triggered apoptosis of activated T lymphocytes is prevented by dendritic cells through a CD58-dependent mechanism
Experimental Hematology 27: 1402-1408 (1999-09-01)
1998
Westermann J; Aicher A; Qin Z; Cayeux S; Daemen K; Blankenstein T; Doerken B; Pezzutto A
Retroviral interleukin-7 gene transfer into human dendritic cells enhances T cell activation
Gene Therapy 5: 264-271 (1998-01-01)
Daniel PT; Kroidl A; Kopp J; Sturm I; Moldenhauer G; Doerken B; Pezzutto A
Immunotherapy of B-cell lymphoma with CD3x19 bispecific antibodies: costimulation via CD28 prevents "Veto" apoptosis of antibody-targeted cytotoxic T cells
Blood 92 (12): 4750-4757 (1998-12-15)
Daniel PT; Kroidl A; Cayeux S; Scholz C; Sturm I; Blankenstein T; Pezzutto A; Doerken B
Retroviral B7.1 gene transfer in cancer cells protects cytotoxic T cells from deletion by "veto" apoptosis
Advances in Experimental Medicine and Biology 451: 265-276 (1998-01-01)
1997
Aicher A; Westermann J; Cayeux S; Willimsky G; Daemen K; Blankenstein T; Uckert W; Doerken B; Pezzutto A
Successful retroviral mediated transduction of a receptor gene in human dendritic cells: feasibility of therapy with gene-modified antigen presenting cells
Experimental Hematology 25: 39-44 (1997-01-01)
Cayeux S; Richter G; Becker C; Beck C; Aicher A; Pezzutto A; Doerken B; Blankenstein T
Lack of correlation between rejection of tumor cells co-expressing interleukin 2 and B7.1 and vaccine efficiency
European Journal of Immunology 27: 1657-1662 (1997-01-01)